Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Abstracts In Press
    • Archives
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Abstracts In Press
    • Archives
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Review ArticleClinical Review

Basal Insulin Therapy in Type 2 Diabetes

M. Angelyn Bethel and Mark N. Feinglos
The Journal of the American Board of Family Practice May 2005, 18 (3) 199-204; DOI: https://doi.org/10.3122/jabfm.18.3.199
M. Angelyn Bethel
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark N. Feinglos
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    Figure 1.

    Idealized pattern of insulin secretion for a healthy individual who has consumed 3 standard meals: breakfast (B), lunch (L), and dinner (D). HS, bedtime.6

  • Figure 2.
    • Download figure
    • Open in new tab
    Figure 2.

    Time-activity profiles (hourly mean values) of insulin glargine and NPH insulin in patients with type 2 diabetes.24

Tables

  • Figures
    • View popup
    Table 1.

    Key Pharmacodynamic Properties for Different Insulin Preparations6,28

    Insulin PreparationOnset of ActionPeak Action (hours)Duration of Action (hours)
    Lispro5 to 15 minutes1 to 23 to 4
    Aspart5 to 15 minutes1 to 23 to 4
    Regular30 to 60 minutes2 to 46 to 8
    NPH1 to 3 hours5 to 713 to 16
    Lente1 to 3 hours4 to 813 to 20
    Ultralente2 to 4 hours8 to 14<20
    Glargine2 to 4 hoursFlat>24
    • NPH, neutral protamine Hagedorn.

PreviousNext
Back to top

In this issue

The Journal of the American Board of Family Practice: 18 (3)
The Journal of the American Board of Family Practice
Vol. 18, Issue 3
1 May 2005
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Basal Insulin Therapy in Type 2 Diabetes
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 15 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Basal Insulin Therapy in Type 2 Diabetes
M. Angelyn Bethel, Mark N. Feinglos
The Journal of the American Board of Family Practice May 2005, 18 (3) 199-204; DOI: 10.3122/jabfm.18.3.199

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Basal Insulin Therapy in Type 2 Diabetes
M. Angelyn Bethel, Mark N. Feinglos
The Journal of the American Board of Family Practice May 2005, 18 (3) 199-204; DOI: 10.3122/jabfm.18.3.199
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Pathophysiology of Type 2 Diabetes
    • Targets for Glucose Control
    • Conclusions
    • Strength of Recommendation (SORT)
    • Notes
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
  • Google Scholar

More in this TOC Section

  • Interpretating Normal Values and Reference Ranges for Laboratory Tests
  • Non-Surgical Management of Urinary Incontinence
  • Screening and Diagnosis of Type 2 Diabetes in Sickle Cell Disease
Show more Clinical Reviews

Similar Articles

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire